This stock has been known to soar after good news.
The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the ...
Q4 2025 Management View CEO Stephan Tanda emphasized "very strong top line performance" for Q4, with reported sales growing 14% to $963 million and core sales up 5%. Tanda noted, "Adjusted EBITDA ...
Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med ...
Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and ...
AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the ...
The next 12 months will be important for the drugmaker.
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to drive ...
We feel now is a pretty good time to analyse Island Pharmaceuticals Limited's ( ASX:ILA ) business as it appears ...
NervGen Pharma Corp. ('NervGen” or the 'Company') (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...
The Yogi Adityanath government is organising Pharma Conclave 1.0 in Lucknow on February 3 to position Uttar Pradesh as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results